SCHEMBL3485625

SCHEMBL3485625

CCOc1ccccc1NC(=O)CN1CCC(N(C(C)C)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
UBE2N P61088 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
CACNA1B Q00975 4/20 0.48
LMNA P02545 4/20 0.47
CACNA1C Q13936 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
KCNT1 Q5JUK3 1/20 0.43
KCNT2 Q6UVM3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486183 0.88 LMNA (0.48) KMT2AMEN1TDP1CYP2D6CYP2C19
SCHEMBL3484838 0.84 NPSR1 (0.53) CYP2D6CYP2C19CACNA1BLMNACACNA1C
SCHEMBL3485607 0.83 CACNA1B (0.56) KMT2AMEN1UBE2NCACNA1BLMNA
SCHEMBL3485918 0.83 TSHR (0.56) CYP2D6CYP2C19CACNA1BLMNAALDH1A1
SCHEMBL3485824 0.82 ALDH1A1 (0.52) CACNA1BLMNAALDH1A1HSD17B10DRD4
SCHEMBL3485265 0.82 ALDH1A1 (0.47) CACNA1BLMNACACNA1CALDH1A1HSD17B10
SCHEMBL3485489 0.82 L3MBTL1 (0.51) CACNA1BLMNACACNA1CALDH1A1HSD17B10
SCHEMBL8086157 0.81 CACNA1B (0.49) KMT2ACACNA1BCACNA1C
SCHEMBL3485300 0.81 SMN1; SMN2 (0.52) KMT2ACYP2D6CYP2C19CACNA1BLMNA
SCHEMBL3485688 0.81 ALDH1A1 (0.50) KMT2AMEN1CACNA1BLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B KMT2A 2462/4885MEN1 3113/4885UBE2N 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.